Ambi 40pse/400gfn/20dm
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
Every FDA drug recall initiated in 2013, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
2,085 recalls, newest first.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
CGMP Deviations: Products are underdosed or have an incorrect dosage regime.
Presence of Foreign Tablets/Capsules: Bottles of lansoprazole 30 mg delayed-release capsules may contain topiramate 100 mg tablets.
Labeling: Incorrect or missing lot and/or expiration date. The product was mistakenly labeled with an expiration date of 10/16 instead of 01/16.
Non-Sterility: Confirmed customer complaint of product contaminated with mold.
Superpotent: Drug product active ingredients were formulated incorrectly (too high) with respect to the label strength.
Presence of Foreign Tablets/Capsules: Recall is being conducted due to a foreign capsule found in one bottle.
Cross Contamination with Other Products: Product was mixed with another type of mouth wash.
Crystallization: Active pharmaceutical ingredient is precipitating in product solution.
CGMP Deviations: Pharmaceutical for injection was not manufactured according to Good Manufacturing Procedures.
Tablet/Capsule Imprinted with Wrong ID; a portion of the tablets could contain the incorrect debossing on one side of the tablet U2 instead of U3.
Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white particles goes into the solution.
Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white particles goes into the solution.
Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white particles goes into the solution.
Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. If the product is shaken or warmed the white particles goes into the solution.
Microbial Contamination of Non-Sterile Product(s): The product has the potential to be contaminated with Bulkholderia gladioli.
Subpotent Drug: OOS (out of specification) assay result at the 12 month stability time point.